CA2992483C - Quantitative peri-orbital application of ophthalmology drugs - Google Patents

Quantitative peri-orbital application of ophthalmology drugs Download PDF

Info

Publication number
CA2992483C
CA2992483C CA2992483A CA2992483A CA2992483C CA 2992483 C CA2992483 C CA 2992483C CA 2992483 A CA2992483 A CA 2992483A CA 2992483 A CA2992483 A CA 2992483A CA 2992483 C CA2992483 C CA 2992483C
Authority
CA
Canada
Prior art keywords
fluoro
carbonyl
amino
isopropyl ester
acid isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2992483A
Other languages
English (en)
French (fr)
Other versions
CA2992483A1 (en
Inventor
David Woodward
Weizhen Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenivision Inc
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of CA2992483A1 publication Critical patent/CA2992483A1/en
Application granted granted Critical
Publication of CA2992483C publication Critical patent/CA2992483C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
CA2992483A 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs Active CA2992483C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/829,789 2015-08-19
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (2)

Publication Number Publication Date
CA2992483A1 CA2992483A1 (en) 2017-02-23
CA2992483C true CA2992483C (en) 2024-03-19

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992483A Active CA2992483C (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Country Status (9)

Country Link
US (1) US9820954B2 (enExample)
EP (1) EP3337474A4 (enExample)
JP (1) JP6924429B2 (enExample)
KR (1) KR102685479B1 (enExample)
CN (1) CN108135873A (enExample)
AU (1) AU2016308105B2 (enExample)
CA (1) CA2992483C (enExample)
MX (1) MX391627B (enExample)
WO (1) WO2017031137A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CN110996964A (zh) * 2017-06-30 2020-04-10 杰尼视界公司 用于毛发生长的制剂
GB2597731A (en) * 2020-07-31 2022-02-09 Imperial College Innovations Ltd Preterm labour
JP2024506872A (ja) * 2021-02-05 2024-02-15 ジェニヴィジョン インク． Ｅｐ２受容体アゴニストの眼窩周囲投与のための組成物および方法
CA3212050A1 (en) * 2021-03-18 2022-09-22 Weizhen Wang Methods and compositions for treating eye diseases
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
EP1755732A4 (en) 2004-04-23 2008-01-16 Mystic Pharmaceuticals Inc DISPENSING SYSTEM FOR MEDICINAL PRODUCTS IN SEVERAL SINGLE DOSES
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
WO2006133411A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
US20090318422A1 (en) 2006-08-28 2009-12-24 Akiharu Isowaki Ophthalmic percutaneous absorption type preparation
US20080107644A1 (en) * 2006-10-31 2008-05-08 Alcon Manufacturing, Ltd. Pai-1 binding modulators for the treatment of ocular disorders
DK2173407T3 (da) 2007-07-02 2020-04-27 Hoffmann La Roche Anordning til indgivelse af lægemiddel
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
MX2010005012A (es) 2007-11-08 2010-06-23 Aciex Therapeutics Inc Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
CN101939288A (zh) * 2008-02-05 2011-01-05 阿斯特兰德英国有限公司 用于治疗高眼压的二氟联苯酰胺衍生物
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
EP2544757A4 (en) 2010-03-09 2013-11-06 Toxcure Inc MICRONADEL DEVICE FOR NASAL DISTRIBUTION
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
EP2755944B1 (en) * 2011-09-16 2017-06-14 Sanofi Biarylderivatives,their preparation and their therapeutic application
KR102029513B1 (ko) 2011-11-15 2019-10-07 알러간, 인코포레이티드 사이클로스포린 제2형의 지속 작용 제형
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Also Published As

Publication number Publication date
JP2018528169A (ja) 2018-09-27
MX2018001918A (es) 2018-11-09
EP3337474A1 (en) 2018-06-27
KR20180042348A (ko) 2018-04-25
EP3337474A4 (en) 2019-04-10
WO2017031137A1 (en) 2017-02-23
US9820954B2 (en) 2017-11-21
CN108135873A (zh) 2018-06-08
AU2016308105B2 (en) 2021-05-27
US20170049734A1 (en) 2017-02-23
CA2992483A1 (en) 2017-02-23
KR102685479B1 (ko) 2024-07-15
AU2016308105A1 (en) 2018-02-15
MX391627B (es) 2025-03-21
JP6924429B2 (ja) 2021-08-25

Similar Documents

Publication Publication Date Title
AU2016308105B2 (en) Quantitative peri-orbital application of ophthalmology drugs
US8637054B2 (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
CN111867560B (zh) 包含噻吗洛尔的药物组合物
US10792288B2 (en) Preservative free brimonidine and timolol solutions
US20090318549A1 (en) Combination treatment of glaucoma
US11857537B2 (en) Use of prostacyclin antagonists for treating ocular surface nociception
CA2807081A1 (en) Preservative free bimatoprost and timolol solutions
JP2021191806A (ja) 眼科用清涼組成物
TWI852041B (zh) 採用長春西汀治療近視的方法
US20230372274A1 (en) Compositions and methods for periorbital administration of ep2 receptor agonists
IL191552A (en) Suxanimide derivatives for reducing ocular pressure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210526

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260401

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713